Business Wire

TFF Pharmaceuticals Comments on Animal Studies in the Development of High Potency Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its ...
Yahoo Finance

Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clinical Development Against COVID-19

MENLO PARK, Calif. and AUSTIN, Texas, June 22, 2021 (GLOBE NEWSWIRE) -- Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and TFF Pharmaceuticals, ...
Business Wire

TFF Pharmaceuticals, Inc. and Augmenta Bioworks, Inc. Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies

AUSTIN, Texas & MENLO PARK, Calif.--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company, and Augmenta Bioworks, Inc., a biotechnology company enabling ...
Yahoo Finance

TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering ...

FORT WORTH, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug ...
Nasdaq

TFF Pharmaceuticals Announces Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID ...

USAMRIID to study use of TFF technology to formulate dry powder neutralizing antibodies and vaccines against national priority biodefense threats for pulmonary delivery Under the terms of the CRADA, ...
GEN

Achieving Process Intensification with Single-Pass TFF

The biopharmaceutical industry produces highly complex and effective medicines to treat challenging diseases. However, changing dynamics in the industry are placing significant pressure on existing ...
Nasdaq

Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clinical Development Against COVID-19

AUG-3387 Active Against All Variants Tested Including the UK (B.1.1.7), South African (B.1.351), Indian (B.1.617.1), and Brazil (P.1) Variants MENLO PARK, Calif. and AUSTIN, Texas, June 22, 2021 ...